Biomarkers in substance use disorders.
The prevention and treatment of substance use disorders (SUDs), including addiction, would benefit from having better biomarkers for the classification of patients into categories that are reproducible and have predictive validity. Direct measurement of drugs or their metabolites in various body fluids constitutes a clinically valuable biomarker but one that can only be used to corroborate acute or relatively recent drug use. Thus, there is an urgent need for biomarkers that reflect chronic drug exposure as well as biomarkers that predict or correlate with disease trajectories and treatment responses. Advances in tools and technologies to investigate genetics, epigenetics and epitranscriptomics, and human brain function and neurochemistry (brain imaging tools including EEG) offer unprecedented opportunities for the development of such biomarkers. Progress in this area will not only enhance our ability to screen and treat patients with SUDs but also accelerate research on the neurobiological processes that underlie SUDs.
†National Institute on Drug Abuse and ‡National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland 20892, United States.
Nora D
ND
Volkow
†National Institute on Drug Abuse and ‡National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland 20892, United States.
George
G
Koob
†National Institute on Drug Abuse and ‡National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland 20892, United States.
Ruben
R
Baler
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D006801:Humans; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000378:metabolism*
D015415:Biomarkers
Addiction; EEG; MRI; PET; dopamine; endophenotype; epigenetics; genetics